Post

How to get URL link on X (Twitter) App

On the Twitter thread, click on or icon on the bottom
Click again on or Share Via icon
Click on Copy Link to Tweet
Paste it above and click "Unroll Thread"!
More info at Twitter Help

Stephen V Liu, MD

Apr 27, 2020 • 6 tweets • 8 min read • Read on X

#OncoAlert #AACR20 Results from phase II study of camrelizumab (SHR-1210, anti-PD-1) plus apatinib in #SCLC presented by Dr. Jie Wang. Camrelizumab is approved in China for Hodgkin lymphoma and has shown promise in HCC. Here, results from single arm phase II. #LCSM

#OncoAlert #AACR20 Stage I included three different schedules of apatinib delivery (camrelizumab is given IV q2w). The apatinib 375mg qday schedule was chosen for stage 2. Included chemo-sensitive and resistant #SCLC, using a 90-day platinum-free interval cutoff. #LCSM

#OncoAlert #AACR20 Patient characteristics reveal a slightly higher proportion of never-smokers (10/47, 21%). #SCLC strongly linked to smoking but can be seen in never smokers (4.5% in IMpower 133). Spontaneous transformation from #EGFR? Different outcomes in this group? #LCSM

#OncoAlert #AACR20 Camrelizumab plus apatinib qday had a RR of 34% including a 32.3% RR in chemo-resistant #SCLC. Encouraging activity. Median duration of response 6.2 months with many ongoing responses. Recall 3L nivo RR 11.9%, 3L pembro RR 19.3%. Is this notably better? #LCSM

#OncoAlert #AACR20 RR encouraging but hard to interpret single arm phase II. What is the contribution of apatinib? VEGFR2 + PD1 is an exciting combination but would we have seen the same results (but less tox) with camrelizumab alone? Need a comparator arm. #LCSM

#OncoAlert #AACR20 Adverse events included #VEGF-related tox. How does this apply in IMp133/CASPIAN world where IO is delivered with 1L therapy? I would welcome more novel agents for #SCLC, but hoping to see biomarker work from this trial and a follow up randomized effort. #LCSM

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @StephenVLiu

Stephen V Liu, MD

@StephenVLiu

Apr 23, 2023

Dr. Shun Lu presents interim results from the perioperative NEOTORCH study at the #ASCOPlenarySeries. Randomized pts with resectable stage II/III NSCLC to perioperative chemotherapy with toripalimab (anti-PD1) vs placebo. Another entry in the perioperative space? #LCSM

Includes resectable stage II/III (AJCC v8), EGFR/ALK wild type NSCLC. Pts receive 3 cycles of neoadjuvant chemotherapy + toripalimab vs placebo then surgery then 1 more cycle of adjuvant chemo (+tori/pbo) then 13 doses of maintenance toripalimab vs placebo. #ASCOPlenarySeries

First interim EFS analysis only for stage III. Includes 404 pts - but 926 screened. Would be interesting to see specific eligibility criteria not met in screening process. Reminder of how selected trial populations are and value of future real-world analyses. #ASCOPlenarySeries

Read 11 tweets

Stephen V Liu, MD

@StephenVLiu

Apr 16, 2023

Impressive data from #AEGEAN at #AACR23 from Dr. John Heymach and colleagues. This is the first of several phase III peri-operative IO studies in resectable NSCLC combining neoadjuvant chemo-immunotherapy followed by adjuvant immunotherapy.

Included stage IIA-IIIB (AJCC v8) with no EGFR/ALK & excluded pts who would require pneumonectomy. Large study with n=801 (CM816 was n=358). Pts received 4 cycles (not 3) of platinum-based chemo with durvalumab (anti-PDL1) or placebo, then surgery, then durvalumab / placebo x 1y.

Almost 75% received carboplatin over cisplatin. Global study; fairly even PDL1 distribution. 80% of pts went to surgery, 78% completed resection (90-95% of those were R0). Overall, 66% of pts began adjuvant phase (but 90% of those who had an R0 resection had adjuvant therapy).

Read 9 tweets

Stephen V Liu, MD

@StephenVLiu

Dec 8, 2022

There is a lot to consider in this first-line study of the #KRAS G12C inhibitor adagrasib plus pembrolizumab from #ESMOImmuno22. Some pleasant surprises in terms of safety. Definitely encouraging but need to see a bit more to be sold on this strategy. 🤔 #LCSM

We're looking for synergy with the two agents - more than an additive effect. Reason to believe there will be based on preclinical data showing the effect on T-cell infiltration from #KRAS inhibition. Similar to what has been shown with MEK inhibition. #ESMOImmuno22

The first-line dataset includes the phase Ib KRYSTAL-1 and the phase II KRYSTAL-7. In KRYSTAL-1 (n=7), 4/7 had a response and all were durable (>9m). G3 TRAEs in 4 pts (lipase elevation, LFTs, muscular pain, pneumothorax). #ESMOImmuno22

Read 10 tweets

Stephen V Liu, MD

@StephenVLiu

Sep 19, 2022

@ZPiotrowskaMD

Dr. @ZPiotrowskaMD presents initial results from the ELIOS trial at #ESMO22 - molecular profiling of #EGFR mutant NSCLC after progression on 1L osimertinib.

In this study of highly motivated pts at esteemed sites, evaluable paired biopsy at PD only available in 46/115 pts (40%). Interestingly, 75 pts (65%) had paired biopsy but 27 failed NGS (23%). Speaks somewhat to the real world feasibility of a repeat biopsy approach. #ESMO22

Common co-mutations at baseline included TP53, EGFR amp, and CDKN2A loss. Acquired alterations included MET amp, EGFR C797S, ALK fusion, NKX2-1 amp. Mostly mutually exclusive. #ESMO22

Read 5 tweets

Stephen V Liu, MD

@StephenVLiu

Sep 11, 2022

Dr. Silvia Novello presents 5y update on KEYNOTE 407 (platinum plus tax and +/- pembrolizumab for 1L squamous NSCLC #ESMO22

With longer follow up, OS favors pembrolizumab arm with mOS 17.2 vs 11.6m (OS HR 0.71) in squamous NSCLC. 5y OS rate 18.4% vs 9.7%. PFS benefit (HR 0.62) and higher RR across PDL1 strata. #ESMO22

For patients who complete 2y of pembrolizumab, 3y OS rate (after completing 2y pembro) was 70% - though not all of those patients are cured (44% were alive without PD or subsequent therapy). #ESMO22

Read 4 tweets

Stephen V Liu, MD

@StephenVLiu

Sep 11, 2022

@marinagarassino

Dr. @marinagarassino presents 5-year efficacy and safety update of KEYNOTE-189 (1L carboplatin plus pemetrexed +- pembrolizumab in non-squamous NSCLC) #ESMO22

KEYNOTE 189 is our SOC and has shown a consistent benefit including improving OS even with a crossover rate of 57%. #ESMO22

KEYNOTE 189 shows sustained OS benefit with longer follow up and a 5y OS rate of 18.4% with an OS HR of 0.60. Better PFS and OS also observed. Benefit across PDL1 strata. No new safety signals . #ESMO22

Read 5 tweets

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Share this page!

Enter URL or ID to Unroll

Stephen V Liu, MD

Try unrolling a thread yourself!

More from @StephenVLiu

Stephen V Liu, MD

Stephen V Liu, MD

Stephen V Liu, MD

Stephen V Liu, MD

Stephen V Liu, MD

Stephen V Liu, MD

Did Thread Reader help you today?

Don't want to be a Premium member but still want to support us?

Send Email!